James Kevin Symancyk
James Kevin Symancyk's purchase track record
James Kevin Symancyk has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/24/2025 | BBWI | $351K | +45.9% | +14.9% | +12.1% |
| 3/31/2025 | SIG | $862K | +37.8% | +68.1% | +18.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
BBWI shares jump 8.7% amid product innovation news. Bath & Body Works stock rose 8.7% recently, a move linked to its push into sensitive-skin products and broader product innovation. This strategy aims to support pricing as consumers look for value. The company also has a low P/E ratio of 4.5, which some analysts view as undervalued, though questions remain about its long-term outlook.
Transaction History
| SIG | ▲ Buy | Grant | 384 | $0 | 8/21/2026 | View on chart |
| BBWI | ▲ Buy | Grant | 7,970 | $0 | 6/11/2026 | View on chart |
| SIG | ▲ Buy | Grant | 386 | $0 | 5/22/2026 | View on chart |
| SIG | ▼ Sell | Tax Withholding | 8,590 | $733K | 4/2/2026 | View on chart |
| SIG | ▲ Buy | Grant | 45,343 | $0 | 3/24/2026 | View on chart |
| SIG | ▲ Buy | Grant | 215 | $0 | 2/20/2026 | View on chart |
| SIG | ▼ Sell | Tax Withholding | 4,179 | $380K | 12/2/2025 | View on chart |
| BBWI | ▲ Buy | Open Market | 22,500 | $351K | 11/24/2025 | View on chart |
| SIG | ▲ Buy | Grant | 222 | $0 | 11/21/2025 | View on chart |
| SIG | ▲ Buy | Grant | 244 | $0 | 8/22/2025 | View on chart |
| BBWI | ▲ Buy | Grant | 5,641 | $0 | 6/5/2025 | View on chart |
| SIG | ▲ Buy | Grant | 327 | $0 | 5/23/2025 | View on chart |
| SIG | ▲ Buy | Grant | 64,480 | $0 | 4/2/2025 | View on chart |
| SIG | ▲ Buy | Open Market | 15,000 | $862K | 3/31/2025 | View on chart |
| SIG | ▲ Buy | Grant | 35,710 | $0 | 12/2/2024 | View on chart |
| BBWI | ▲ Buy | Grant | 3,844 | $0 | 6/27/2024 | View on chart |
| BBWI | ▲ Buy | Grant | 3,572 | $0 | 6/8/2023 | View on chart |
| BBWI | ▲ Buy | Grant | 3,091 | $0 | 5/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Signet Shares Rise 8.4% Post-Earnings; Blue Nile Partners with Royal Asscher
Signet shares have climbed 8.4% since the last earnings report, moving against a broader market dip. The company also announced that its Blue Nile brand is partnering with Royal Asscher, a move that may strengthen its product lineup. With an average analyst target of $125.90, the stock remains well below that level, sitting near its 52-week high of $110.20.
Signet Shares Rise 8.4% Post-Earnings; Blue Nile Partners with Royal Asscher. Signet shares have climbed 8.4% since the last earnings report, moving against a broader market dip. The company also announced that its Blue Nile brand is partnering with Royal Asscher, a move that may strengthen its product lineup. With an average analyst target of $125.90, the stock remains well below that level, sitting near its 52-week high of $110.20.